BOSTON – "This is like deja vu all over again." The often-used famous quote by Yogi Berra is appropriate since not only has Boston strong ties to baseball, but also to the growth of biotechnology. Read More
Nearly 14 years after the approval of Herceptin (trastuzumab), Genentech Inc. has a second approved drug targeting HER2, Perjeta (pertuzumab). Read More
As the 72nd annual scientific sessions of the American Diabetes Association (ADA) drew to a close last week, the world's leading diabetes experts were left in no doubt that the market for glucagon-like peptide-1 (GLP-1) receptor agonists is becoming highly competitive. Read More
